Excess risk of cancer in patients with primary venous thromboembolism: a national, population-based cohort study

Murchison, John T; Wylie, Lesley; Stockton, Diane

doi:10.1038/sj.bjc.6601964

Cited by 119 publications

(94 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Since the first report back in 1868 (Trousseau, 1868), many publications have dealt with the association of thromboembolic and malignant diseases (Prandoni et al, 1992;Baron et al, 1998;Sorensen et al, 1998;Sutherland et al, 2002;Deitcher, 2003;Lee et al, 2003;Murchison et al, 2004;Otten et al, 2004). A recently published study reported VTE in 7.6% of 1041 patients with solid tumours (Sallah et al, 2002), whereas we found VTE in 7.7% of 1038 patients with malignant lymphoma with a higher incidence in high-grade than in low-grade lymphoma (Mohren et al, 2005).…”

mentioning

confidence: 45%

Increased risk of venous thromboembolism in patients with acute leukaemia

et al. 2006

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 45%

Increased risk of venous thromboembolism in patients with acute leukaemia

et al. 2006

View full text Add to dashboard Cite

show abstract

“…The most common underlying malignant diseases were ovarian cancer, Hodgkin lymphoma, and non-Hodgkin lymphoma. 11 In a study of 192 patients with critical limb ischemia, the reported incidence of occult malignancy was 11.5%. 12 Approximately half of occult malignancies can be detected with a limited workup based on medical history, clinical examination, and routine laboratory tests.…”

Section: Thrombosis Ratesmentioning

confidence: 99%

Assessing the Risk and Prognosis of Thrombotic Complications in Cancer Patients

Kyriazi

Theodoulou

2013

Archives of Pathology &Amp; Laboratory Medicine

View full text Add to dashboard Cite

Context.—Cancer is characterized by the development of a prothrombotic state. Approximately 15% to 20% and 1.5% to 3.1% of cancer patients develop venous and arterial thrombosis, respectively, whereas 18% to 20% of idiopathic venous events are caused by an occult neoplasia. The highest risk is observed in hematologic, gastrointestinal, and lung malignancies, as well as in patients with active disease, especially in the first 3 months after cancer diagnosis. Hospitalization, surgical interventions, and implanted venous devices increase the thrombotic risk. Patients with metastatic disease, febrile neutropenia, infections, and severe comorbidities experience more frequently a thrombotic event. A contemporary prechemotherapy predictive model incorporates both clinical and biologic parameters, such as the primary cancer site, platelet count, white blood cell count, hemoglobin, use of erythropoietic agents, and body mass index. Several studies aim to clarify the prognostic value of tissue factor, P-selectin, thrombin generation, microparticles, and D-dimers. Objectives.—To summarize current views on epidemiology, risk factors, and predictive variables, discussing the future perspectives and existing limitations in clinical practice. Data Sources.—Review of published literature, including review papers, epidemiologic studies, and clinical trials, in online medical databases. Conclusions.—The thrombogenic properties of tumor cells affect the prognosis and quality of life for the cancer population. Despite the improved awareness and prompt use of thromboprophylaxis, recent studies reported increased rates of thrombotic events, whereas the annual risks for thrombosis recurrence and bleeding are 21% and 12%, respectively. The clinical use of risk factors and prognostic parameters could allow for patient risk stratification and individualization of anticoagulant treatment.

show abstract

“…Patients with clinically overt cancer may develop venous thromboembolism (VTE) at any stage of the disease (Agnelli, 1997;Rickles and Levine, 2001), aggravated by surgery, chemotherapy and intravenous catheters (Rickles and Levine, 2001). Occasionally, the thromboembolic event may occur before the clinical presentation of the cancer, and it is well known that the risk of a first cancer diagnosis is greatly increased in the year immediately after VTE (Prandoni et al, 1992;Baron et al, 1998;Sørensen et al, 1998Sørensen et al, , 2000Murchison et al, 2004).…”

mentioning

confidence: 99%

The risk of a second cancer after hospitalisation for venous thromboembolism

et al. 2005

View full text Add to dashboard Cite

Although venous thromboembolism (VTE) is common in patients with cancer, it is not known if it is associated with risk of a second malignancy. Using the Danish Cancer Registry and National Registry of Patients, we studied a population-based cohort of 6285 patients with cancer who had an episode of VTE. The risk of a second cancer was compared with that among 30 713 cancer patients without VTE, matched for age, sex, cancer site and year of diagnosis. Overall, the relative risk for a second cancer diagnosis was 1.3 (95% confidence interval (CI) 1.1 -1.4). However, the excess risk varied with the time from the initial cancer diagnosis to the thrombotic event. If the thrombotic episode occurred within the first year, the relative risk for a second cancer was 1.0 (95% CI 0.9 -1.3), but if the VTE occurred more than 1 year after the initial cancer, the overall relative risk for a second cancer was 1.4 (95% CI 1.2 -1.7), with strong associations for cancers of the digestive organs, ovary and prostate. The association between VTE and subsequent incident cancer extends to patients who already have had a cancer diagnosis.

show abstract

Excess risk of cancer in patients with primary venous thromboembolism: a national, population-based cohort study

Cited by 119 publications

References 15 publications

Increased risk of venous thromboembolism in patients with acute leukaemia

Increased risk of venous thromboembolism in patients with acute leukaemia

Assessing the Risk and Prognosis of Thrombotic Complications in Cancer Patients

The risk of a second cancer after hospitalisation for venous thromboembolism

Contact Info

Product

Resources

About